Looks like they are getting less money up front now. The original deal was for up to US$150 million in upfront and milestone payments prior to product launch but that has been reduced to US$112.5 million. Though it is good that they feel confident to move forward with the program, and that Grünenthal are sticking around.
Ann: Mesoblast Update on Chronic Low Back Pain Program, page-4
-
- There are more pages in this discussion • 337 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.105(8.37%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.23 | $1.14 | $9.583M | 8.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |